![Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions](https://www.mdpi.com/pharmaceutics/pharmaceutics-12-01074/article_deploy/html/images/pharmaceutics-12-01074-g001.png)
Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions
![Approval lapsed) Trimethoprim Mylan 300mg tablets (Netherlands) | Therapeutic Goods Administration (TGA) Approval lapsed) Trimethoprim Mylan 300mg tablets (Netherlands) | Therapeutic Goods Administration (TGA)](https://www.tga.gov.au/sites/default/files/styles/full_lg/public/2022-11/trimethoprimmylannetherlandsmedsurge.png?itok=S4QK4PK4)
Approval lapsed) Trimethoprim Mylan 300mg tablets (Netherlands) | Therapeutic Goods Administration (TGA)
![Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions](https://www.mdpi.com/pharmaceutics/pharmaceutics-12-01074/article_deploy/html/images/pharmaceutics-12-01074-g005.png)